⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of BioCina and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
BioCina
↗Adelaide, Australia
BioCina is a global, end-to-end contract development and manufacturing organization (CDMO) specializing in the development and cGMP manufacture of microbial-based biological pharmaceuticals. The company provides services ranging from cell line development, process development, and analytical development to cGMP clinical and commercial manufacturing for microbial, plasmid DNA (pDNA), and mRNA modalities.
Headquartered in Adelaide, Australia, BioCina operates state-of-the-art facilities that were formerly part of the Pfizer/Hospira network. Following a strategic merger with NovaCina in early 2025, the company expanded its capabilities to include sterile fill-finish services in Perth, positioning itself as a comprehensive, integrated provider for global biopharmaceutical clients.
CLASSIFICATION
SIZE & FINANCIALS
Employees:101-200
Founded:2020
Ownership:private
Status:operating
FUNDING
Stage:Private Equity-Backed
Investors:Bridgewest Group
PIPELINE
Stage:N/A
Lead Drug Stage:N/A
Modalities:Microbial, pDNA, mRNA, LNP
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Bridgewest Group
Key Partnerships:NovaCina (Strategic merger for integrated drug substance and fill-finish solutions), University of Adelaide (mRNA vaccine collaboration)
COMPETITION
Position:Challenger
Competitors:Wacker Chemie, BDI biotech, Enduro
LEADERSHIP
Key Executives:
Mark W. Womack - CEO
Dr. Thomas Broudy - CEO (Appointed)
Scientific Founders:Ian Wisenberg
LINKS
Website:biocina.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with BioCina. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.